Related Experiment Video
Updated: Nov 26, 2025
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Heparin-coated vs. Non-coated Cardiopulmonary Bypass Circuits: Comparing Immediate Results with Different Target
Muhammet Onur Hanedan1, Mehmet Ali Yürük1, Ali Kemal Arslan1
1Department of Cardiovascular Surgery, University of Health Sciences, Ahi Evren Thoracic and Cardiovascular Surgery Training and Research Hospital, Trabzon, Turkey.
Insights
Heparin-albumin-coated circuits in cardiac surgery reduced hospital stay and blood transfusions compared to non-coated circuits. This approach is safe, leading to satisfactory patient outcomes during cardiopulmonary bypass.
Area of Science:
- Cardiovascular Surgery
- Biomaterials Science
Background:
- Cardiopulmonary bypass (CPB) circuits are essential for cardiac surgery.
- Optimizing circuit biocompatibility and anticoagulation management is crucial for patient safety and outcomes.
Purpose of the Study:
- To compare the immediate postoperative results of heparin-albumin-coated circuits versus non-coated circuits in patients undergoing on-pump cardiac surgery.
Main Methods:
- A prospective study involving 241 patients undergoing on-pump cardiac surgery.
- Patients were divided into two groups: those receiving heparin-albumin-coated circuits and those receiving non-coated circuits.
- Key metrics including activated clotting times (ACT), in-hospital mortality, stroke rates, ICU stay, hospital stay, drainage, and erythrocyte transfusion requirements were analyzed.
Main Results:
- Activated clotting times (ACT) during CPB were significantly shorter in the heparin-albumin-coated group (355.64±34.12) compared to the non-coated group (560.38±90.20) (P=0.001).
- No significant differences were observed in in-hospital mortality, postoperative stroke rates, or ICU length of stay between the groups.
- The heparin-albumin-coated group demonstrated significantly better outcomes regarding overall hospital stay, reduced drainage, and a lower need for erythrocyte transfusions.
Conclusions:
- Heparin-albumin-coated circuits, combined with a target ACT of 300 seconds during CPB, are safe for cardiac surgery.
- This approach leads to a very satisfactory clinical course, evidenced by improved postoperative recovery metrics.
Objective:
To compare immediate postoperative results in patients receiving heparin-albumin-coated and non-coated circuits.
Methods:
A total of 241 patients undergoing on-pump cardiac surgery were divided into two groups: those receiving heparin-coated circuits (Bioline®, Maquet Cardiopulmonary AG., Hirrlingen, Germany) and those receiving non-coated circuits (Maquet Cardiopulmonary AG., Hirrlingen, Germany).
Results:
Activated clotting times (ACT) during cardiopulmonary bypass (CPB) were significantly shorter in the heparin-albumin-coated group than in the non-coated group (355.64±34.12 vs. 560.38±90.20, respectively, P=0.001). In-hospital mortality and postoperative stroke rates and lengths of intensive care unit stay were similar between the groups; in contrast, in the heparin-albumin-coated group, patients had significantly better outcomes for hospital stay, drainage, and need for erythrocyte transfusion.
Conclusion:
Heparin-coated circuits and reduced level of systemic heparinization with 300 seconds of target ACT level in cardiac surgery under CPB are safe and result in a very satisfactory clinical course.
Related Concept Videos
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins